HIND
Vyome Holdings Inc.

35,216
Mkt Cap
$14.62M
Volume
124,957.00
52W High
$305.00
52W Low
$1.75
PE Ratio
-0.01
HIND Fundamentals
Price
$2.59
Prev Close
$2.61
Open
$2.57
50D MA
$3.40
Beta
0.08
Avg. Volume
2.34M
EPS (Annual)
-$1,382.95
P/B
5.69
Rev/Employee
$444,777.78
$2.47
Loading...
Loading...
News
all
press releases
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
Vyome Holdings, Inc. (Vyome) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced that it...
Business Wire·6d ago
News Placeholder
More News
News Placeholder
Independent Analyst Values Vyomes VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
Vyome Holdings, Inc. (Vyome) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced key...
Business Wire·21d ago
News Placeholder
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) announced its subsidiary, LiveChain, Inc. (Livechain or LICH) (OTC Markets: LICH) has executed a binding letter of intent (LOI) with Remus Capital, a...
Business Wire·2mo ago
News Placeholder
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) announced the final results from an investigator-initiated Phase 2 proof of concept study of VT-1953 topical gel in people with malignant fungating wounds...
Business Wire·2mo ago
News Placeholder
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
Vyome Holdings, Inc., (Vyome) (NASDAQ: HIND), a next-generation inflammation-focused company leveraging the USIndia innovation corridor, today announced its financial results and a series of...
Business Wire·3mo ago
News Placeholder
Vyome Holdings Announces Results of Annual Shareholder Meeting
Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) announced it held its annual shareholder meeting on October 28, 2025. All 3 Class I directors up for re-election Krishna K. Gupta, Shiladitya Sengupta, and...
Business Wire·3mo ago
News Placeholder
HIND Stock Rallies 70% Pre-Market Today – Find Out Why
In a preclinical model of anterior uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score, Vyome said.
Stocktwits·5mo ago
<
...
1
>

Latest HIND News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.